case_images: PMC10469624_01
case_images: Brain MRI on admission of the patient: (A) T1 weighted imaging (T1WI) showed low signal intensity; (B) T2 weighted imaging (T2WI) showed high signal intensity; (C) Fluid attenuated inversion recovery (FLAIR) showed a high signal; (D) Diffusion weighted imaging (DWI) showed more pronounced hyperintensity than T2WI.
case_images: fneur-14-1178272-g001.jpg
case_images: PMC10469624_01_fneur-14-1178272-g001.jpg
case_images: fig1
case_images: The magnetic resonance imaging (MRI) examination of the head suggested that the lesions of the splenium of the corpus callosum, combined with the medical history, could be consistent with the MR manifestations of toxic encephalopathy (Figure 1). The patient was given betamethasone (8 mg, once a day), torasemide (20 mg, twice a day), alanylglutamine (10 g, once a day), lansoprazole (30 mg, twice a day), reduced glutathione (1.8 gram once a day) and nutritional support.
case_images: (A-D) Day 7 brain MRI:The splenial lesion of the corpus callosum had improved and might be considered as RESLES.
case_images: fneur-14-1178272-g002.jpg
case_images: PMC10469624_01_fneur-14-1178272-g002.jpg
case_images: fig2
case_images: On the 7th day of treatment, brain MRI showed that the abnormal signal of the splenium of the corpus callosum might be considered as RESLES (Figure 2).
case_images: Day 14 brain CT: The splenial lesion of the corpus callosum was no longer visible on computed tomography scan.
case_images: fneur-14-1178272-g003.jpg
case_images: PMC10469624_01_fneur-14-1178272-g003.jpg
case_images: fig3
case_images: On day 14, the splenial lesion of the corpus callosum is no longer visible on computed tomography scan (Figure 3).